Development & Validation of RP-HPLC Method for the Determination of Oseltamivir  Phosphate API by Bano, Tabassum et al.
Journal of Progressive Research in Chemistry [JPRC] 
                                                                                                                                                                       ISSN 2454-3136 
  
Volume 2, Issue 1 available at www.scitecresearch.com/journals/index.php/jprc                                                                   69 
 
SCITECH                                                                           Volume 2, Issue 1 
RESEARCH ORGANISATION                                             July 10, 2015 
Journal of Progressive Research in Chemistry 
www.scitecresearch.com 
Development & Validation of RP-HPLC Method for the Determination 
of Oseltamivir Phosphate API 
 
Tabassum Bano
1
*, Rupesh Dudhe
2 
,  Nitin Kumar
1 
1
Oxford College of Pharmacy, Massorie Industrial Area, UPSIDC, MG Road, Ghaziabad., U. P,  India. 
2
Department of Pharmacy, Galgotias University, Yamuna Expressway, Greater Noida,U. P.  India.  
 
 
Abstract  
A simple and rapid liquid chromatographic assay for the evaluation of potentially counterfeit oseltamivir 
phosphate has been developed and assessed. The present study describes the development of a new, 
simple, reproducible RP-HPLC method for the quantitative determination of Oseltamivir phosphate (OSP). 
The proposed method utilizes C-18 column 100mm x 4.6mm at 25◦C with isocratic run using Methanol and 
Acetonitrile (50:50 v/v) at a flow rate of 1ml/min. and UV detection at 227 nm. The method was statistically 
validated for linearity, ruggedness, robustness, precision, and accuracy. The calibration curve was obtained in 
the concentration range of 5-35μg/ml with correlation coefficient 0.996. The robustness of the method has 
been studied by slightly varying the chromatographic conditions. 
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Introduction:  
Oseltamivir phosphate is an ester prodrug, which is rapidly and extensively hydrolyzed in-vivo to its active metabolite 
Oseltamivir carboxylate, a potent and selective inhibitor of influenza virus neuraminidase [1]. It is considered the leading 
currently available antiviral to counter a serious epidemic or pandemic outbreak of influenza [2]. Oseltamivir is 
chemically Ethyl (3R, 4R, 5S)-4-acetylamino-5-amino-3-pentan- 3-cyclohexene-1-carboxylate phosphate. It has an 
antiviral activity. The structure of oseltamivir possesses a hydrophobic moiety (Fig. 1). Oseltamivir’s hydrophobic group 
is responsible for its poor oral absorption; thus, the phosphate salt has been developed that allows oral administration of 
this drug. OSP is a prodrug that is rapidly and extensively metabolized via hepatic esterases to oseltamivir carboxylate 
(OC), the active form, a potent and selective inhibitor of influenza virus neuraminidase [3–4].     
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Fig1:  Chemical Structure of Oseltamivir Phosphate 
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Tamiflu® will be unaffordable for many poor countries, increasing the chance of a pandemic. Generic manufacturers 
would fill any potential market shortages of Tamiflu® in the event of an epidemic and sell generic versions at a 
considerably lower price than Tamiflu® in countries where the patent is not valid. Following the potential for counterfeit 
copies of Tamiflu, there is a risk that medicinal products supplied may be substandard or counterfeit versions.[8]  
The aim of the present work was to develop and validate a simple, fast and reliable isocratic RP-HPLC method with UV 
detection for the determination of OSP in Tamiflu® and generic versions. The important features and novelty of the 
proposed method included simple sample treatment with sonication of small amount of powder sample at ambient 
temperature, centrifugation, dilution; short elution time (less than 5 min) with internal standard eluted prior to OSP; short 
analysis time (less than 30 min); good precision (R.S.D. less than 1.5%) and high recovery (greater than 95%). 
Confirmation of the applicability of the developed method validated according to the International Conference on 
Harmonization (ICH), to determination of OSP in Tamiflu® capsules and generic Tamiflu capsules has been also 
performed. 
Summary of Reported Analytical Studies on the Drug of Oseltamivir Phosphate 
S. M. Malipatil et al., (2011) reported RP-HPLC method for the estimation of Oseltamivir phosphate in bulk drug and in 
dosage form.Chromatography was carried out on purosphere column using a mixture of mobile phase i.e. Ammonium 
acetate buffer 6.9 pH and Acetonitrile (60:40 v/v) as the mobile phase at a flow rate of 1 mL/min with detection 
performed at 220 nm. The retention time was found to be (RT = 4.89 min). The detector response was linear in the 
concentration of 1-20 mcg/mL. The limit of detection and limit of quantification were 1.0 and 10.0 mcg/mL respectively. 
The percentage assay of Oseltamivir phosphate was 99.77%.  
M. Espinosa Bosch et al., (2010) developed the stability of Oseltamivir Phosphate in oral aqueous solutions containing 
the preservative sodium benzoate was studied by a stability indicating HPLC-method. The separation was achieved on 
RP-18 column using a gradient of mobile phase A (aqueous solution of 50 mM ammonium acetate) and mobile phase B 
(60% acetonitrile/40% mobile phase A), at a flow rate 0.5 mL/min. UV detection at 220 nm, and the retention time was 
found to be (RT = 5.0 min).  
Michael D. Green et al., (2008) developed and validated a simple method for the determination of Oseltamivir 
phosphate quality by colorimetric and liquid chromatographic methods. The mobile phase contained a combination of 
30% acetonitrile and 70% 0.05 M bicarbonate buffer, pH 10, at flow rate 1 mL/min to achieve component separation. 
Absorbance was monitored at 254 and 220 nm. Total analysis time was found to be 4 min.  
Balasubramanian Narasimhan et al., (2008) reported stability indicating RP-HPLC method development and 
validation for Oseltamivir active pharmaceutical ingredient (API). The proposed RP-HPLC method utilized Kromasil 
C18, 5 microm, 250 mm x 4.6 mm i.d. column (at ambient temperature), gradient run (using acetonitrile and triethylamine 
as mobile phase), effluent flow rate was (1.0 ml/min). UV detection at 215 nm for analysis of Oseltamivir and retention 
time was found to be 4.2 min.  
Joseph-Charles et al., (2007) reported development and validation of a rapid HPLC method for the determination of 
oseltamivir phosphate in Tamiflu and generic versions. The proposed HPLC method utilized Zorbax CN column (150 
mm x 4.6mm; 5 microm), a mobile phase consisted of methanol and 0.04 M formic acid pH 3.0 (50:50, v/v) at flow rate 
1.2 (mL/min) absorbance was monitored at 226 nm and the retention time was found to be 3.40-2.25 min. 
A. P. Winiarski et al., (2007) reported preparation and stability of extemporaneous oral liquid formulation of 
Oseltamivir using commercially available capsules. RP C18 column (250 x 4.6mm, 5 µm) was used. The ratio of mobile 
phase was 0.075 mol/L potassium phosphate monobasic solution (pH-3): methanol 89:11 (v/v).  UV detection was 
performed at 215nm. The retention time was detected at (RT = 4.3 min).  
Material and Method: 
Material and Chemicals:  
 Acetonitrile and Methanol of HPLC grade was procured from SIGMA –ALDRICH chemicals Pvt. Ltd. 
Maharashtra, India. 
 Oseltamivir phosphate was provided by MATRIX PHARMACEUTICALS, Hyderabad; India as a gift sample. 
Equipment: 
 Waters 2487 Isocratic HPLC system with 515 LC pump, SPD-20A Detector, EMPOWER -2software. 
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Chromatographic conditions: 
 Mobile Phase : Methanol and Acetonitrile (50:50% v/v) 
 Column: C18 Column (Purosphere column) 250mm X 4.6mm with 5μm particle size. 
 Flow rate : 1.0 ml/min 
 Column Temp : 25oC 
 Program : Isocratic 
 Wavelength : 227 nm 
 Run time : 1.542 mint 
 Sample Volume : 20μl 
Procedure: 
Preparation of Standard Oseltamivir Phosphate Solution 
Preparation of Standard Solution: Accurately weighed 10.0 mg of pure drug Oseltamivir phosphate was taken in 
clean, dry 10 ml volumetric flask and dissolved in 10 ml volume of mobile phase (Methanol: Acetonitrile) resulting in 
1000.0 µg/ml of drug concentration (Stock solution). Now pipette out 1 ml of this solution and diluted to 100 ml with the 
above solvent system, resulting in 100 µg/ml of the drug concentration. Now made different working solutions of the 
drug (having different concentrations) by pipette out different volume from the stock solution, and make the volume of 
all the working solutions upto 10 ml with above mobile phase. 
Assay of the Formulation: 20 capsule of OSP each containing 75 mg of OSP were taken and the powder was mixed. An 
accurately weighed portion of the powder to 100mg was taken and dissolved up to 100ml with the mobile phase 
(Methanol: Acetonitrile) i.e. called 1st stock . 10ml of this solution is taken into 100ml volumetric flask and dissolved up 
to the mark with the above solvent system(2nd stock) Now 1ml of the sample solution from 2nd stock is taken in a 10 ml 
volumetric flask and the volume is made up to the mark with above solvent system i.e.( 10μg/ml) Solution. The mean of 
peak area of drug solution for n=6 were calculated and the drug content in the tablet was quantified by using the 
regression equation. The same procedure was followed for the estimation of OSP in other pharmaceutical formulations.  
Result And Discussion 
As per the ICH guidelines the method validation parameters checked were linearity, precision, LOQ, LOD, accuracy, 
ruggedness and robustness. 
Linearity: The method was linear in the range of 5-30μg/ml. 
Precision: Precision was demonstrated by Interday and intraday variation studies. In the intraday   and Interday studies 
the solutions were injected 6times and %RSD was calculated which was found to be less than 1.5%. From the data 
obtained the RP-HPLC method appeared precise. 
Accuracy: The accuracy of the method was determined by adding known quantities of drug to previously analysed 
formulations and reanalysed by the proposed method. The accuracy of the method was supported by high recovery values 
obtained from developed method. 
LOD and LOQ: LOD and LOQ were determined for the proposed method. Mean for the six readings were taken for the 
same concentration and the limit of detection was found to be 5.57µg/ml and quantitation limit was 16.90µg/ml, this 
shows the sensitivity of the method. 
Robustness: Robustness of the method was observed by making slight deliberate changes in the chromatographic 
conditions like variation in the flow rate (i.e. 0.9ml/min and 1.1ml/min). It was observed that there were no marked 
changes in chromatograms, which demonstrate the robustness of the method. 
Ruggedness Studies: were carried out with Waters 2487 with the software of Empower 2 system, %RSD was calculated 
for six readings and was found to be 1.206 and 0.5943 respectively. 
Journal of Progressive Research in Chemistry [JPRC] 
                                                                                                                                                                       ISSN 2454-3136 
  
Volume 2, Issue 1 available at www.scitecresearch.com/journals/index.php/jprc                                                                   72 
 
 
I - Standard Curve of HPLC  Method for the Estimation of Oseltamivir Phosphate. 
 
 
III - Recovery studies for Oseltamivir Phosphate using proposed RP-HPLC method. 
 
Level 
(Approx) 
Standard 
Added (mg) 
Peak Area 
Standard Recovered 
(mg) 
%  Recovery 
Mean 
Recovery 
RSD 
 80% 40 320681 39.884 099.71 
099.92 0.2669 100% 50 401334 49.915 099.83 
120% 60 483527 60.132 100.22 
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Concetration (µg/ml) 
Standard curve of OSP 
Sr. No. 
Conc. 
(µg/mL) 
Peak area 
1. 5 87654 
2. 10 137890 
3. 15 213459 
4. 20 287654 
5. 25 364295 
6. 30 443245 
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Conclusion 
The present developed RP-HPLC method is sensitive, precise, economical and rapid. The retention time was 1.522min. 
Whereas the run time was set for 10min. the method was used for the quantitative estimation of two different samples 
and the %age purity was found to be 99.66% and 99.78%. Hence the proposed RP-HPLC method can be conveniently 
adopted for the routine analysis and quality control of the drug. 
Table 1: HPLC Estimation of Oseltamivir Phosphate 
 Parameters Results 
Calibration Range (µg/ml) 5-30 µg/ml 
LOD 5.57 µg 
LOQ 16.90 µg 
Regression Coefficient 0.996 
Slope (Y) 14583x 
System precision 1.4364 
Method precision 1.2481 
Retention Time 1.542 mint 
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